Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Nerivio Remote Electrical Neuromodulation Could Serve as Alternate Treatment for Chronic Migraine
October 4th 2022No statistical differences were found between REN and the standard of care medications, in any of the effectiveness outcomes of pain single-treatment pain relief and pain freedom, nor in consistency of pain relief and pain freedom.
CNM-Au8 Shows Survival Benefit in HEALEY ALS Trial, But Fails to Meet End Points
October 3rd 2022Despite not meeting its primary and secondary end points, CNM-Au8 will continue to be evaluated in an open-label extension in HEALEY ALS and could potentially be offered in an expanded access protocol program.
Reactions, Ramifications, and Forward Progress of Newly Approved AMX0035 for ALS
October 1st 2022Justin Klee and Josh Cohen, cofounders and cochief operating officers, Amylyx Pharmaceuticals, answered questions related to the new approval of AMX0035 for ALS and how it changes the treatment landscape going forward.
Ofatumumab Outperforms Teriflunomide in Newly Diagnosed, Treatment-Naïve Multiple Sclerosis
September 28th 2022Consistent with the overall population, newly diagnosed, treatment-naïve patients with MS showed better relapse rates, all-cause disability worsening—including progression independent of relapse activity—with ofatumumab over teriflunomide.
Dimethyl Fumarate Shows Low MS Relapse Rates, Encouraging Safety After 13-Year Analysis
September 26th 2022Over a long-term follow-up, a high proportion of patients were compliant to therapy, with adverse events mild-to-moderate in nature, regardless of individuals being on continuous treatment or switched from placebo.
NeuroVoices: Thomas M. Wisniewski, MD, on Raising Awareness for World Alzheimer’s Day
September 21st 2022The director of NYU Langone’s Alzheimer’s Disease Research Center and Center for Cognitive Neurology provided perspective on raising awareness for World Alzheimer’s Day and the ongoing challenges patients with the disease face.
Several Genetic Loci Show Increased Risk of Mortality, Cognitive Impairment in Parkinson Disease
September 19th 2022One of the identified loci related to clinical progression in Parkinson disease expresses ADORA2A in the cerebellum, which encodes the adenosine A2A receptor, a promising target for therapeutics in PD.
Celebrating the Expansion and Stressing the Importance of Newborn Screening
September 17th 2022The explosion of new science and legislative decisions have expanded the capabilities and reach of newborn screening, providing thousands of families every year an opportunity to seek early, and critical, care for their infants.
NurOwn Treatment Shows Positive Results in Phase 2 Study of Progressive Multiple Sclerosis
September 16th 2022Treatment with NurOwn resulted in response on several secondary outcomes, including timed 25-foot walk, 12-item multiple sclerosis walking scale, and low contrast letter acuity, among others.
Trauma and Discrimination Worsen Migrainous Headache in Sexual and Gender Minority Individuals
September 15th 2022Approximately half of the respondents with a history of headache screened positive for migrainous headache by ID-migraine criterion with most reporting moderate to severe intensity headache.
Increased Tau Burden Observed in Abnormal Central Vascular Hemodynamics
September 15th 2022Patients who demonstrated increased central pulse pressure and forward wave amplitude had greater entorhinal tau burden. These measures were not associated with amygdala, inferior temporal, nor precuneus tau burden.